Schering-Plough's asenapine cleared by FDA

11/26/2007 | MarketWatch

The FDA has accepted Schering-Plough Corp.'s new drug application for asenapine, an oral treatment for schizophrenia and symptoms of bipolar disorder. Schering-Plough owns rights to asenapine through Organon BioSciences NV, which it acquired last week.

View Full Article in:

MarketWatch

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA